1 |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2 |
顾秀瑛, 郑荣寿, 张思维, 等. 2000—2014年中国肿瘤登记地区前列腺癌发病趋势及年龄变化分析[J]. 中华预防医学杂志, 2018, 52(6): 586-592.
|
|
GU X Y, ZHENG R S, ZHANG S W, et al. Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014[J]. Chinese Journal of Preventive Medicine, 2018, 52(6): 586-592.
|
3 |
TROYER J K, BECKETT M L, WRIGHT G L. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids[J]. Int J Cancer, 1995, 62(5): 552-558.
|
4 |
WRIGHT G L, HALEY C, BECKETT M L, et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues[J]. Urol Oncol, 1995, 1(1): 18-28.
|
5 |
AFSHAR-OROMIEH A, MALCHER A, EDER M, et al. Reply to Reske et al.: pet imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions[J]. Eur J Nucl Med Mol Imaging, 2013, 40(6): 971-972.
|
6 |
WERNER R A, DERLIN T, LAPA C, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging[J]. Theranostics, 2020, 10(1): 1-16.
|
7 |
FDA approves 18F-DCFPyL PET agent in prostate cancer[J]. J Nucl Med, 2021, 62(8): 11N.
|
8 |
KOH W J, ABU-RUSTUM N R, BEAN S, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2018, 16(2): 170-199.
|
9 |
METSER U, ORTEGA C, PERLIS N, et al. Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR [J]. Eur J Nucl Med Mol Imaging, 2021, 48(11): 3702-3711.
|
10 |
SONNI I, FELKER E R, LENIS A T, et al. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial[J]. J Nucl Med, 2022, 63(6): 847-854.
|
11 |
DONATO P, ROBERTS M J, MORTON A, et al. Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology[J]. Eur J Nucl Med Mol Imaging, 2019, 46(1): 20-30.
|
12 |
CAGLIC I, SUSHENTSEV N, SHAH N, et al. Comparison of biparametric versus multiparametric prostate MRI for the detection of extracapsular extension and seminal vesicle invasion in biopsy naïve patients[J]. Eur J Radiol, 2021, 141: 109804.
|
13 |
BOESEN L, CHABANOVA E, LØGAGER V, et al. Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology[J]. Eur Radiol, 2015, 25(6): 1776-1785.
|
14 |
POPIŢA C, POPIŢA A R, ANDREI A, et al. Local staging of prostate cancer with multiparametric-MRI: accuracy and inter-reader agreement [J]. Med Pharm Rep, 2020, 93(2): 150-161.
|
15 |
YILMAZ B, TURKAY R, COLAKOGLU Y, et al. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer[J]. Prostate, 2019, 79(9): 1007-1017.
|
16 |
KOSEOGLU E, KORDAN Y, KILIC M, et al. Diagnostic ability of Ga-68 PSMA PET to detect dominant and non-dominant tumors, upgrading and adverse pathology in patients with PIRADS 4-5 index lesions undergoing radical prostatectomy[J]. Prostate Cancer Prostatic Dis, 2021, 24(1): 202-209.
|
17 |
UCAR T, GUNDUZ N, DEMIRCI E, et al. Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: a retrospective study [J]. Prostate, 2022, 82(15): 1462-1468.
|
18 |
ÇELEN S, GÜLTEKIN A, ÖZLÜLERDEN Y, et al. Comparison of 68Ga-PSMA-I/T PET-CT and multiparametric MRI for locoregional staging of prostate cancer patients: a pilot study[J]. Urol Int, 2020, 104(9/10): 684-691.
|
19 |
ARSLAN A, KARAARSLAN E, LEVENT GÜNER A, et al. Comparing the diagnostic performance of multiparametric prostate MRI versus 68Ga-PSMA PET-CT in the evaluation lymph node involvement and extraprostatic extension[J]. Acad Radiol, 2022, 29(5): 698-704.
|
20 |
HOPE T A, EIBER M, ARMSTRONG W R, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial[J]. JAMA Oncol, 2021, 7(11): 1635-1642.
|
21 |
MAURER T, GSCHWEND J E, RAUSCHER I, et al. Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer[J]. J Urol, 2016, 195(5): 1436-1443.
|
22 |
WOO S, SUH C H, KIM S Y, et al. The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: an updated systematic review and diagnostic meta-analysis [J]. AJR Am J Roentgenol, 2018, 210(3): W95-w109.
|
23 |
BUDÄUS L, LEYH-BANNURAH S R, SALOMON G, et al. Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy [J]. Eur Urol, 2016, 69(3): 393-396.
|
24 |
YUMINAGA Y, ROTHE C, KAM J, et al. 68Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy[J]. Asian J Urol, 2021, 8(2): 170-175.
|
25 |
PYKA T, OKAMOTO S, DAHLBENDER M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2016, 43(12): 2114-2121.
|
26 |
ACAR E, BEKIŞ R, POLACK B. Comparison of bone uptake in bone scan and Ga-68 PSMA PET/CT images in patients with prostate cancer[J]. Curr Med Imaging Rev, 2019, 15(6): 589-594.
|
27 |
RUSTHOVEN C G, JONES B L, FLAIG T W, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer [J]. J Clin Oncol, 2016, 34(24): 2835-2842.
|
28 |
SATKUNASIVAM R, KIM A E, DESAI M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis[J]. J Urol, 2015, 194(2): 378-385.
|
29 |
OST P, REYNDERS D, DECAESTECKER K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase Ⅱ trial [J]. J Clin Oncol, 2018, 36(5): 446-453.
|